𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of multiple primary tumors following oral squamous-cell carcinoma

✍ Scribed by Andreas Jovanoic; Ignaz G. H. van der Tol; Engelbert A. J. M. Schulten; Pieter J. Kostense; Nico de Vries; Gordon B. Snow; Isaäc van der Waal

Publisher
John Wiley and Sons
Year
1994
Tongue
French
Weight
441 KB
Volume
56
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of the tumor suppressor
Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas
✍ Flávio J. Pimenta; Dawidson A. Gomes; Paolla F. Perdigão; Alvimar A. Barbosa; Ma 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 232 KB 👁 2 views

## Abstract Oral squamous cell carcinoma (OSCC) is the most common malignant neoplasm of the oral cavity, representing ˜90% of all oral carcinomas and accounting for 3–5% of all malignancies. The __WWOX__ gene (WW‐domain containing oxidoreductase) is a candidate tumor suppressor gene located at 16q

Primary tumor thickness as a risk factor
Primary tumor thickness as a risk factor for contralateral cervical metastases in T1/T2 oral tongue squamous cell carcinoma
✍ Carol M. Bier-Laning; Ramon Durazo-Arvizu; Kamil Muzaffar; Guy J. Petruzzelli 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Objectives/Hypothesis: Contralateral cervical metastases represent an avoidable source of failure in squamous cell carcinoma (SCCa) of the oral tongue. We sought to identify risk factors for the development of contralateral cervical metastases in T1/T2 oral tongue SCCa. ## Study De

Oral squamous cell carcinoma and a clini
Oral squamous cell carcinoma and a clinically negative neck: The value of follow-up
✍ Bart M. Wensing; Matthias A. W. Merkx; Paul F. M. Krabbe; Henri A. M. Marres; Fr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 2 views

## Abstract ## Background In squamous cell carcinoma of the oral cavity (SCCOC), regular follow‐up comprises 5 years of prescheduled visits, irrespective of tumor stage/classification and/or treatment. We analyzed our standard treatment and follow‐up protocol in patients with a preoperative clinic